Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM trial of Tasigna in c-Kit mutated advanced melanoma
NL-OMON37871Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in melanoma, sponsored by Novartis. Primary endpoint: Overall response rate. Planned start Nov 2011; status: withdrawn.
02
Drugs
nilotinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON37871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37871.